Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10267MR)

This product GTTS-WQ10267MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10267MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13678MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC18
GTTS-WQ10636MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ1898MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ1866MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ8147MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ12578MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ6888MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ3123MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW